An enzyme-labeled immunometric assay has been developed for measuring digoxin concentrations in serum or plasma. Unitized, compartmentalized reagents are used with an automated sample-processing instrument. The enzyme activity of the processed sample, which is directly proportional to the digoxin concentration, is measured by using a reagent strip and the Ames Seralyzer#{174} reflectance photometer. The test takes less than 15 mm, and digoxmn concentrations are calculated from a two-point calibration line stored in the instrument. Within-run CVs for controls at four concentrations ranged from 2.3% to 3.8%; between-run CVs were from 1.5% to 2.6%. Results obtained with clinical serum samples correlated well (r >0.96) with those obtained by fluorescent polarization immunoassay (Abbott TDx) and AlA (Clinical Assays and NML). This rapid and convenient method for monitoring digoxin concentrations in serum or plasma is particularly well suited for decentralized sites such as emergency rooms, urgent-care centers, and physicians' offices.
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Digoxin, a cardiac glycoside derived from the leaf of the plant Digitalis lanata, is used to treat congestive heart failure and atrial fibrillation and to manage atrial flutter and paroxysmal tachycardia (1). Its therapeutic range is generally reported to be 0.8 to 2.0 jzg/L in serum. Monitoring digoxin concentrations in serum and observing clinical symptoms can maximize its effectiveness and avoid toxicity (1) (2) (3) (4) (5) .
Methods used to determine the concentration of digoxin in serum or plasma include radioimmunoassay (6), fluorescence polarization immunoassay (7) , fluorescence energy transfer immunoassay (8) , cloned enzyme donor imniunoassay (9), immunometric assay (10), combined liquid chromatography/radioinnmunoassay (11), radial partition immunoassay (12), and a receptor assay (13). We have developed an immunometric assay for digoxin that can be performed in 15 mm when used in conjunction with a dry reagent substrate strip analyzed in an Ames "Seralyzer" reflectance photometer.
In this assay (see Figure 1 , below) an excess of a monoconjugate of 3-galactosidase (EC 3.2.1.23) with a Fab' fragment of an anti-digoxin mouse monoclonal antibody binds the digoxin in the sample. The conjugate not bound to digoxin is then removed by treatment with a capture phase: digitoxigenin bound to polyacrylamide beads via an aminocaproic acid spacer arm. After separation of the capture phase from the assay solution, the /3-D-galactosidase activity of the assay solution is determined by reflectance photometry of a reagent strip containing the substrate dimethylacridinone galactoside (DMAG), to which the sample is applied. This enzyme activity is directly proportional to the digoxin concentration of the sample. Calibrators and controls were prepared by mixing gravimetrically prepared digoxin solutions with heat-treated (60 #{176}C for 60 mm), filtered normal human serum containing 1 g of sodium aside per liter as preservative.
Materials and Methods

Apparatus
Assay Procedure
The assay procedure is shown in Figure 1 . Remove the cap from the conjugate vial, and pipet 30 pL of serum or After the start button of the sample processor is pushed, fIle sample is automatically processed by rocking for 2 minutes. followed by standing ford minutes. During this time the digosin is bound by the corilugate.
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The sample processor then rotates the vial assembly to mix the liquid with he caoture ohase for 4 minutes and stops with the mixture in the inst as shown. The conlugate that did not bind digOxin In step 3 is bound by Iris capture phase. S The connector is removed, a fitter is inserted in the vial containing themixture, and a 30 yrL sample oldie filtrate is transferred to a reagent strip on the Seralyzer so that itsfl-galactosidase activity can be determined. The digoxin concentratiOn isdirectly proportional to the enzyme activity at tie conugate in the processed sample filtrate. Secure a hollow connector over the tops of both vials in the vial holder, and press the start button of the sample processor. The sample is now automatically processed for 12 mm. During this time, the vial holder is rocked for 2 mm to mix the sample with conjugate reagent, incubated statically for 6 min to complete complexation of the conjugate with digoxin, and rotated for 4 mm to mix the capture phase with the sample/conjugate solution and thereby remove any free conjugate from the solution. After processing, remove and discard the connector and push a piston ifiter into the capture-phase compartment, which now contains the assay mixture. The filtrate in the center of the piston filter contains the conjugate, which was bound to the digoxin from the sample.
Place a reagent strip on the Seralyzer reflectance photometer, pipet a 30-.tL aliquot of ifitrate onto the reagent strip, and push the start key to begin sample analysis. The reflectance is monitored from 40 to 60 s after sample application and converted to a function, L(R), which is linearly proportional to chromophore concentration. The reactivity of the sample is compared with a stored calibration curve, and a calculated digoxin concentration is displayed.
For 
Results
The DMAG Reagent Strip
The spectra of DMAG and its chromophore, dimethylacridinone, are shown in Figure 2 . Upon hydrolysis of the DMAG, color develops with a peak in the absorption spectrum at 634 nm. We monitored the color formed at 630 nm when conjugate was applied to DMAG reagent strips. 
Binding of Digoxin to Conjugate
We determined the time needed for 0.4 nmoIJL conjugate to bind the digoxin in aS p,gtL sample, a concentration that is at the upper end of the assay range. The binding was completed 8 mm after the sample was mixed with the conjugate.
Samples containing lower concentrations of digoxmn were found to bind conjugate more quickly than the 5 pgfL sample. A time of 8 mm was, therefore, chosen for the first incubation step of the assay.
Binding of Conjugate to Capture Phase
The time courses for the removal of conjugate from 
Criticality of Timing after Sample Processing
In a decentralized laboratory, the operator may not be available to complete the assay immediately after sample processing. Therefore, we examined the criticality of the timing between the completion of sample processing and the insertion of the piston filter. There was no change in the assayed digoxin concentration if the insertion of the piston filter was delayed for up to 60 mm after sample processing was completed. We also examined how long the sample could stand after the piston filter was inserted. There was no change in the assayed digoxin concentration when the ifitrate was used up to 4 h after the filter was inserted.
Dose Response to Digoxin
The assay for digoxin in serum was performed as shown in Figure 1 , and its dose response is shown in Figure 6 . The dose response is linear between 0 and 5 g/L, so a two-point calibration can be used. We chose 0.6 and 3.0 gfL digoxmn for the calibrator concentrations.
Other Assay Variables
Precision and accuracy. These were determined by calibrating the Seralyzer reflectance photometer and assaying several concentrations of serum controls, in triplicate. This was repeated 20 times. Table 1 The 40-to 60-s L(R) rate is plotted vs the digoxin concentration System calibration. The validity of using a stored calibration line was tested by calibrating a Seralyzer and then assaying seven clinical serum specimens at four-to six-day intervals during a month. A freshly thawed aliquot of each serum was used at each time point. The data in Table 2 show that a calibration line can be used for 30 days.
Cross-reactivity. We tested the cross-reactivity of some drugs that might be prescribed with digoxin, compounds with chemical structures similar to digoxmn, digoxin metabolites, and common over-the-counter medications.
At the concentrations in serum noted in parentheses, the following compounds increased the assayed value of a 2.0 pg/L digoxmn control by <20%: acetaminophen 
Interferences.
Endogenous compounds were examined for interference with the assay. Digoxin was added to samples of serum containing various concentrations of either bilirubin, cholesterol, or triglycerides, which were then assayed. No interference was found up to 150 mg of bilirubin, 3.25 g of cholesterol, or 15 g of triglycerides per liter. To control sera containing digoxin we added either ascorbic acid or uric acid. No interference was seen for the former up to 100 mgfL or for the latter up to 150 mgfL.
Interference from hemoglobin was studied by adding digoxin to hemolyzed plasma and assaying. Non-hemolyzed plasma from the same individual was used as a control. We found a positive interference corresponding to about 1 pg of digoxin per liter for each milligram of hemoglobin per liter; therefore hemolyzed samples must not be used.
To examine the effect of anticoagulants on the assay, we 
Comparison with Other Methods
Clinical serum specimens were assayed by this method and by Abbott's TDx method (see Figure 8 tional to the digoxin concentration in the sample. Only two pipetting steps are used, which minimizes the opportunity for operator error. A sample-processing instrument performs all of the critically timed steps and reagent transfers. Both of the antibody-conjugate binding reactions (i.e., the binding of the digoxin to the conjugate and the binding of the excess conjugate to the capture phase) proceed to relatively stable equilibria; this allows for maximum operator flexibility. Thus the assay can be performed by an operator who has 1 mm to set up the sample processing and, after 12 mm of processing, has another 2 mm within the next hour to complete the assay, using a dry-reagent strip in the Seralyzer reflectance photometer. In a decentralized setting, the 15-mm assay time would allow a physician to determine a patient's serum digoxin concentration while the patient is still at the office.
The linear dose response to digoxin allows use of a two-point calibration that is stable for 30 days. The assay is both precise and accurate, and results correlate well with those obtained by other immunoassays for digoxin. The assay is not cross-reactive to drugs that might be commonly co-prescribed with digoxin, common over-thecounter medications, naturally occurring hormones, or the digoxin metabolite dihydrodigoxin. The assay is crossreactive to deslanoside, digitoxin, digoxigenin, and gitoxin, compounds structurally similar to digoxin. However, none of these compounds are co-prescribed with digoxin and therefore should not cause any problem for the use of the assay.
Some serum samples contain endogenous "digoj4ike immunoreactive factors" that cause falsely high digoxin concentrations in certain immunoassays (20) . Matheke and Valdes (21) examined the present assay and found very low cross-reactivity with DLIF. The format for this digoxin immunoassay is particularly appropriate for emergency rooms, urgent-care centers, and physicians' offices, where rapid testing is desirable (22).
